NeuroBo Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco
14 January 2020 - 1:00AM
Business Wire
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology
company focused on multimodal, disease-modifying therapies for
neurodegenerative diseases, today announced that it will present at
Biotech Showcase 2020, to be held January 13-15, 2020 at the Hilton
San Francisco Union Square.
Presentation Details
Presenter: Richard J. Kang, Ph.D., president and chief executive
officer Date: Wednesday, January 15, 2020 Time: 9 a.m. (PST) Track:
Franciscan D (Ballroom Level) Venue: Hilton San Francisco Union
Square Hotel, 333 O’Farrell Street, San Francisco, CA
A link to the live audio webcast of the presentation will be
available in the Investors & Media section of the company’s
website: https://www.neurobopharma.com/news. An archived version of
the webcast will be available following the presentation.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc., is focused on novel treatments
for neurodegenerative diseases affecting millions of patients
worldwide. The company’s multimodal approach has the potential to
address the multiple underlying mechanisms of neurodegenerative
diseases, alleviate symptoms and slow disease progression. The
company’s lead drug candidate, NB-01, for the treatment of painful
diabetic neuropathy (PDN) has been shown in a Phase 2 study to
significantly reduce pain symptoms associated with PDN with a
superior safety profile when compared to currently available
treatments. Enrollment in the first study in the Phase 3 program
for NB-01 in the U.S. is expected to begin in the first half of
2020, with a target enrollment of approximately 460 subjects with
PDN. NeuroBo’s IND-ready second drug candidate, NB-02, is focused
on the treatment of Alzheimer’s disease and neurodegenerative
diseases associated with the pathological dysfunction of tau
proteins in the brain.
NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman,
professor of neurology at Harvard Medical School and renowned
expert in neuropathic pain, and JK BioPharma Solutions, a
biotechnology consulting company, to commercialize natural
product-based research into ethical medicines. For more
information, visit: https://www.neurobopharma.com/.
About Biotech Showcase
Biotech Showcase™ is an investor and networking conference
devoted to providing private and public biotechnology and life
sciences companies with an opportunity to present to, and meet
with, investors and pharmaceutical executives in one place during
the course of one of the industry's largest annual health care
investor conferences. Investors and biopharmaceutical executives
from around the world gather in San Francisco during this
bellwether week, which sets the tone for the coming year. Now in
its eleventh year, this rapidly growing conference features
multiple tracks of presenting companies, plenary sessions,
workshops, networking and an opportunity to schedule one-to-one
meetings. Biotech Showcase is produced by Demy-Colton and EBD
Group. Both organizations have a long history of producing high
quality programs that support the biotechnology and broader life
sciences industry.
Forward Looking Statements
Any statements in this press release that are not statements of
historical fact constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements include, but are not limited to,
statements regarding the therapeutic potential, timing and nature
of human trials and potential regulatory approval of NeuroBo’s
clinical programs and pipeline. Forward-looking statements are
usually identified by the use of words, such as “believes,”
“anticipates,” “expects,” “intends,” “plans,” “may,” “potential,”
“will,” “could” and similar expressions. Actual results may differ
materially from those indicated by forward-looking statements as a
result of various important factors and risks. These factors, risks
and uncertainties include, but are not limited to: NeuroBo’s plans
to develop and commercialize its product candidates; the timing of
completion of NeuroBo’s planned clinical trials; the timing of the
availability of data from NeuroBo’s clinical trials; NeuroBo’s
plans to research, develop and commercialize its current and future
product candidates; NeuroBo’s ability to successfully collaborate
with existing collaborators or enter into new collaborations and to
fulfill its obligations under any such collaboration agreements;
the clinical utility, potential benefits and market acceptance of
NeuroBo’s product candidates; NeuroBo’s commercialization,
marketing and manufacturing capabilities and strategy; the impact
of government laws and regulations; NeuroBo’s ability to protect
its intellectual property position; and NeuroBo’s need for
additional financing to fulfill its stated goals; and other factors
discussed in the "Risk Factors" section of SEC filings the combined
company makes with the SEC from time to time. In addition, the
forward-looking statements included in this press release represent
NeuroBo’s views as of the date hereof. NeuroBo anticipates that
subsequent events and developments will cause its views to change.
However, while NeuroBo may elect to update these forward-looking
statements at some point in the future, NeuroBo specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing NeuroBo’s views as of any
date subsequent to the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200113005056/en/
Nicole Franklin Racepoint Global 617.624.3264
nfranklin@racepointglobal.com
NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From Apr 2024 to May 2024
NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From May 2023 to May 2024